Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024) | ||
By: PR Newswire Association LLC. - 23 May 2020 | Back to overview list |
|
NEW YORK, May 22, 2020 /PRNewswire/ -- The global antiviral drugs market is expected to reach US$70.95 billion in 2024, increasing at a CAGR of 2.10%, for the duration of 2020-2024. The factors such as, increasing prevalence of HIV infections, upswing in international tourism, growth in geriatric population, increasing pharmaceutical R&D spending, rapid urbanization, upsurge in healthcare spending and growing awareness about various viral diseases are expected to drive the growth of the market. However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations. A few notable trends may include accelerating growth rate of infectious diseases, increasing focus on telehealth, growth in pharmaceutical Merger & acquisitions and emergence of new infectious diseases. Read the full report: https://www.reportlinker.com/p05896999/?utm_source=PRN The global antiviral drugs market is fragmented into branded drugs and generic drugs. Branded drugs dominate the market owing to the increased levels of trust and reliability associated with branded pharmaceutical companies among customers. However, generic drugs are also gaining widespread popularity among customers due to the low cost factor, which is likely to raise its share in global market in coming years. View original content:http://www.prnewswire.com/news-releases/global-antiviral-drugs-market-by-type-application--region-insights--forecast-with-potential-impact-of-covid-19-2020-2024-301064559.html SOURCE Reportlinker |
||
|
||
Copyright 2020 PR Newswire Association LLC. | Back to overview list |